

Execution keeping pace with ambition

BFSI - NBFCs ▶ Company Update ▶ September 20, 2026

CMP (Rs): 352 | TP (Rs): 410

About a year after listing, Tata Capital continues to impress with its execution, with growth, asset quality, credit costs, and profitability broadly tracking guidance. We recently interacted with the management to assess the current environment amid a host of external factors, including: 1) RBI's draft amendment directions restricting NBFCs from offering revolving credit; 2) excess systemic liquidity driven by strong FCNR (B) deposit mobilization by banks; and 3) sustained macro uncertainty amid persistently high crude prices and renewed risks from US trade sanctions. Overall, the management response provided sufficient comfort on TATACAP's ability to deliver its FY28 guidance of: 1) AUM growth of ~23%-25% over FY25-28; 2) credit cost and NNPA<1%; 3) cost-to-income ratio of ~33%-34%; and 4) ROA/ROE of 2.5%-2.7%/17%-18%. We reiterate ADD on the stock, with broadly unchanged estimates and an unchanged Sep-27E TP of Rs410.

Clarity awaited on revolving credit, impact manageable

RBI has received stakeholder feedback on the [Draft Amendment Directions](#) and sought data and clarifications on NBFCs' revolving credit facilities, including LAS, business loan overdrafts, supply chain financing, and personal loan overdrafts. Under the strictest definition of a "revolving facility", ~8-9% of Tata Capital's AUM falls into this category. However, based on customer behavior, ~3-4% could transition to "term loans", limiting the potential impact to no more than 5% of AUM even under a stringent regulatory framework. Given that a large portion of SMEs receiving revolving credit lines from NBFCs have no such facilities from banks, the deeper reach and origination capabilities of NBFCs and fintechs, and the regulatory framework already considering undrawn overdraft lines in liquidity and capital requirements, it is less likely that RBI will bar NBFCs from this business, in our view.

FCNR deluge unlikely to drive lower COF for NBFCs

Despite excess systemic liquidity driven by strong FCNR(B) deposit mobilization by banks, interest rates for one-year and longer tenors have not declined and have, in fact, increased. Looking ahead, with the upcoming shallow rate-hike cycle, COF is likely to increase, however, the company's ALM ensures no negative impact on margin. The FCNR-led strong deposit growth could drive aggressive lending by banks in prime home loans and highly rated corporate loans.

Progressing on guided path of growth, credit costs, and profitability

Supported by robust credit demand across the retail, SME, and corporate segments, the company continues to grow within its guided range and expects growth to strengthen further once the Tata Motors Finance book returns to growth from 3Q. On the margin front, the impact of stronger growth in high-yielding products should start flowing through from 2H, while 2Q margins are expected to broadly track 1Q levels. On operating leverage and credit costs, the company's actual experience continues to be better than the management expectations.

Target Price – 12M	Sep-27
Change in TP (%)	-
Current Reco.	ADD
Previous Reco.	ADD
Upside/(Downside) (%)	16.5

Stock Data	TATACAP IN
52-week High (Rs)	390
52-week Low (Rs)	296
Shares outstanding (mn)	4,244.9
Market-cap (Rs bn)	1,494
Market-cap (USD mn)	15,583
Net-debt, FY27E (Rs mn)	NA
ADTV-3M (mn shares)	2.7
ADTV-3M (Rs mn)	1,017.3
ADTV-3M (USD mn)	10.6
Free float (%)	0.0
Nifty-50	23,346.4
INR/USD	95.9


Shareholding, Jun-26

Promoters (%)	85.4
FPIs/MFs (%)	5.2/3.6

Price Performance

(%)	1M	3M	12M
Absolute	(3.1)	1.9	0.0
Rel. to Nifty	0.3	5.5	0.0

1-Year share price trend (Rs)



Tata Capital: Financial Snapshot (Consolidated)

Y/E Mar (Rs mn)	FY25	FY26	FY27E	FY28E	FY29E
Net profits	36,550	48,909	71,750	94,201	119,434
AUM growth (%)	40.5	20.7	23.3	23.8	24.0
NII growth (%)	57.2	18.5	26.8	26.3	24.7
NIMs (%)	5.1	5.1	5.3	5.4	5.4
PPOP growth (%)	55.1	23.7	33.5	30.3	26.7
Adj. EPS (Rs)	9.7	12.1	16.9	22.2	28.1
Adj. EPS growth (%)	14.5	24.7	38.9	31.4	26.9
Adj. BV (INR)	83.4	108.8	125.8	148.1	176.4
Adj. BVPS growth (%)	31.9	30.4	15.6	17.8	19.1
RoA (%)	1.7	1.8	2.2	2.4	2.4
RoE (%)	13.3	12.7	14.5	16.3	17.5
P/E (x)	36.1	29.0	20.9	15.9	12.5
P/ABV (x)	4.2	3.2	2.8	2.4	2.0

Source: Company, Emkay Research

Avinash Singh

 avinash.singh@emkayglobal.com
 +91-22-66121327

Kishan Rungta

 kishan.rungta@emkayglobal.com
 +91-22-66242490

Exhibit 1: Valuation metrics

			PBV (x)			PER (x)			ROA (%)			ROE (%)			Book value (Rs/sh)			EPS (Rs)		
	Price	Upside	FY27E	FY28E	FY29E	FY27E	FY28E	FY29E	FY27E	FY28E	FY29E	FY27E	FY28E	FY29E	FY27E	FY28E	FY29E	FY27E	FY28E	FY29E
At CMP	352	16.5%	2.8	2.4	2.0	20.9	15.9	12.5	2.2	2.4	2.4	14.5	16.3	17.5	125.8	148.1	176.4	16.9	22.2	28.1
AT TP	410		3.3	2.8	2.3	24.3	18.5	14.6												

Source: Company, Emkay Research

Exhibit 2: Change in estimates


Y/e Mar (Rs mn)	FY27E			FY28E			FY29E		
	Earlier	Revised	Change	Earlier	Revised	Change	Earlier	Revised	Change
AUM	3,370,841	3,370,841	0.0%	4,171,471	4,171,471	0.0%	5,174,623	5,174,623	0.0%
Loan book growth	23.30%	23.30%	0bps	23.75%	23.75%	0bps	24.05%	24.05%	0bps
Net interest income	161,732	160,609	-0.7%	203,350	202,878	-0.2%	253,706	253,052	-0.3%
Total Income	200,737	197,864	-1.4%	251,347	250,265	-0.4%	313,465	312,057	-0.4%
PPOP	129,869	127,876	-1.5%	167,032	166,628	-0.2%	211,655	211,047	-0.3%
Provisions	31,933	31,322	-1.9%	39,861	39,861	0.0%	50,324	50,324	0.0%
PBT	97,937	96,554	-1.4%	127,171	126,767	-0.3%	161,331	160,723	-0.4%
PAT attributable to SH	72,177	71,150	-1.4%	93,802	93,501	-0.3%	119,086	118,634	-0.4%
EPS (Rs)	17.1	16.9	-1.4%	22.2	22.2	-0.3%	28.2	28.1	-0.4%
BVPS (Rs)	126	126	-0.2%	148	148	-0.2%	177	176	-0.2%
Networth	531,392	530,364	-0.19%	625,894	624,566	-0.21%	745,780	743,999	-0.24%
NIMs	5.30%	5.26%	-4bps	5.39%	5.38%	-1bps	5.43%	5.42%	-1bps
NIM + Fees	6.58%	6.48%	-9bps	6.66%	6.64%	-3bps	6.71%	6.68%	-3bps
Cost-to-Income	35.30%	35.37%	7bps	33.55%	33.42%	-13bps	32.48%	32.37%	-11bps
Opex-to-AUM	2.32%	2.29%	-3bps	2.24%	2.22%	-2bps	2.18%	2.16%	-2bps
Credit costs	1.05%	1.03%	-2bps	1.06%	1.06%	0bps	1.08%	1.08%	0bps
GS3	1.80%	1.80%	0bps	1.75%	1.75%	0bps	1.75%	1.75%	0bps
NS3	0.82%	0.82%	0bps	0.83%	0.83%	0bps	0.83%	0.83%	0bps
PCR	55.00%	55.00%	0bps	53.00%	53.00%	0bps	53.00%	53.00%	0bps
ROA	2.25%	2.22%	-3bps	2.38%	2.37%	-1bps	2.44%	2.44%	-1bps
ROE	14.7%	14.5%	-19bps	16.3%	16.3%	-2bps	17.5%	17.5%	-3bps

Source: Company, Emkay Research

This report is intended for Team White Marquee Solutions (team.emkay@whitemarquesolutions)


Story in charts

Exhibit 3: Strong growth momentum to continue over the medium term




Source: Company, Emkay Research

Exhibit 4: Strong disbursement across the product segment




Source: Company, Emkay Research

Exhibit 5: Yields to expand as asset mix improves




Source: Company, Emkay Research

Exhibit 6: Margins to improve on the back of increasing share of high-yield products




Source: Company, Emkay Research

Exhibit 7: Opex to moderate as efficiency improves




Source: Company, Emkay Research

Exhibit 8: Our credit cost estimates are slightly above management guidance of ~1%




Source: Company, Emkay Research

This report is intended for Team White Marquee Solutions (team.emkay@whitemarquesolutions)

Exhibit 9: Asset quality to be stable ahead

Source: Company, Emkay Research

Exhibit 10: Annual ROA/ROE expansion led by improving operating metrics

Source: Company, Emkay Research

This report is intended for Team White Marque Solutions (team.emkay@whitemarquesolutions)

Tata Capital: Consolidated Financials and Valuations

Profit & Loss					
Y/E Mar (Rs mn)	FY25	FY26	FY27E	FY28E	FY29E
Interest Income	257,198	286,522	352,550	446,882	556,093
Interest Expense	150,296	159,853	191,941	244,004	303,041
Net interest income	106,901	126,669	160,609	202,878	253,052
NII growth (%)	57.2	18.5	26.8	26.3	24.7
Non interest income	26,501	29,304	37,255	47,387	59,005
Total income	133,402	155,973	197,864	250,265	312,057
Operating expenses	55,923	60,169	69,988	83,637	101,010
PPOP	77,480	95,804	127,876	166,628	211,047
PPOP growth (%)	55.1	23.7	33.5	30.3	26.7
Provisions & contingencies	28,268	30,229	31,322	39,861	50,324
PBT	49,211	65,575	96,554	126,767	160,723
Extraordinary items	0	0	0	0	0
Tax expense	12,635	16,715	24,804	32,566	41,289
Minority interest	-	-	-	-	-
Income from JV/Associates	(26)	49	0	0	0
Reported PAT	36,550	48,909	71,750	94,201	119,434
PAT growth (%)	9.9	33.8	46.7	31.3	26.8
Adjusted PAT	36,647	48,461	71,150	93,501	118,634
Diluted EPS (Rs)	9.7	12.1	16.9	22.2	28.1
Diluted EPS growth (%)	14.5	24.7	38.9	31.4	26.9
DPS (Rs)	0	0	0	0	0
Dividend payout (%)	0	0	0	0	0
Effective tax rate (%)	25.7	25.5	25.7	25.7	25.7
Net interest margins (%)	5.1	5.1	5.3	5.4	5.4
Cost-income ratio (%)	41.9	38.6	35.4	33.4	32.4
PAT/PPOP (%)	47.2	51.1	56.1	56.5	56.6
Shares outstanding (mn)	3,762.4	4,216.7	4,216.7	4,216.7	4,216.7

Source: Company, Emkay Research

Asset quality and other metrics					
Y/E Mar (Rs mn)	FY25	FY26	FY27E	FY28E	FY29E
Asset quality					
GNPL - Stage 3	39,094	54,678	60,675	73,001	90,556
NNPL - Stage 3	16,340	23,949	27,304	34,310	42,561
GNPL ratio - Stage 3 (%)	1.7	2.0	1.8	1.8	1.8
NNPL ratio - Stage 3 (%)	0.7	0.9	0.8	0.8	0.8
ECL coverage - Stage 3 (%)	58.2	56.2	55.0	53.0	53.0
ECL coverage - 1 & 2 (%)	0.9	0.7	0.8	0.8	0.8
Gross slippage - Stage 3	-	-	-	-	-
Gross slippage ratio (%)	-	-	-	-	-
Write-off ratio (%)	0.9	0.8	0.8	0.7	0.7
Total credit costs (%)	1.3	1.2	1.0	1.1	1.1
NNPA to networth (%)	5.2	5.2	5.1	5.5	5.7
Capital adequacy					
Total CAR (%)	16.9	19.0	17.7	16.7	15.9
Tier-1 (%)	12.8	15.9	14.6	13.6	12.8
Miscellaneous					
Total income growth (%)	54.6	16.9	26.9	26.5	24.7
Opex growth (%)	53.9	7.6	16.3	19.5	20.8
PPOP margin (%)	4.0	3.8	4.2	4.4	4.5
Credit costs-to-PPOP (%)	36.5	31.6	24.5	23.9	23.8
Loan-to-Assets (%)	89.3	92.3	93.0	93.5	93.8
Yield on loans (%)	12.2	11.5	11.6	11.9	11.9
Cost of funds (%)	7.8	7.2	7.2	7.4	7.4
Spread (%)	4.5	4.3	4.3	4.5	4.5

Source: Company, Emkay Research

Balance Sheet					
Y/E Mar (Rs mn)	FY25	FY26	FY27E	FY28E	FY29E
Share capital	37,624	42,167	42,167	42,167	42,167
Reserves & surplus	276,214	416,448	488,198	582,399	701,833
Net worth	313,838	458,615	530,364	624,566	743,999
Borrowings	2,102,229	2,359,769	2,939,374	3,660,466	4,564,018
Other liabilities & prov.	68,583	86,652	93,933	101,942	110,753
Total liabilities & equity	2,484,650	2,905,035	3,563,671	4,386,974	5,418,770
Net loans	2,219,504	2,682,031	3,312,613	4,099,781	5,085,320
Investments	98,664	95,082	104,590	115,049	126,554
Cash, other balances	94,782	36,406	45,340	58,954	80,144
Interest earning assets	2,412,950	2,813,518	3,462,543	4,273,783	5,292,017
Fixed assets	19,264	25,039	28,795	33,114	38,081
Other assets	52,436	66,478	72,333	80,077	88,672
Total assets	2,484,650	2,905,035	3,563,671	4,386,974	5,418,770
BVPS (Rs)	83.4	108.8	125.8	148.1	176.4
Adj. BVPS (INR)	83.4	108.8	125.8	148.1	176.4
Gross loans	2,265,530	2,733,920	3,370,841	4,171,471	5,174,623
Total AUM	2,265,530	2,733,920	3,370,841	4,171,471	5,174,623
On balance sheet	2,265,530	2,733,920	3,370,841	4,171,471	5,174,623
Off balance sheet	0	0	0	0	0
Disbursements	1,423,017	1,696,600	2,171,648	2,823,142	3,726,548
Disbursements growth (%)	35.5	19.2	28.0	30.0	32.0
Loan growth (%)	40.7	20.8	23.5	23.8	24.0
AUM growth (%)	40.5	20.7	23.3	23.8	24.0
Borrowings growth (%)	41.9	12.3	24.6	24.5	24.7
Book value growth (%)	31.9	30.4	15.6	17.8	19.1

Source: Company, Emkay Research

Valuations and key Ratios					
Y/E Mar	FY25	FY26	FY27E	FY28E	FY29E
P/E (x)	36.1	29.0	20.9	15.9	12.5
P/B (x)	4.2	3.2	2.8	2.4	2.0
P/ABV (x)	4.2	3.2	2.8	2.4	2.0
P/PPOP (x)	0.0	0.0	0.0	0.0	0.0
Dividend yield (%)	0	0	0	0	0
Dupont-RoE split (%)					
NII/avg AUM	5.5	5.1	5.3	5.4	5.4
Other income	1.4	1.2	1.2	1.3	1.3
Securitization income	-	-	-	-	-
Opex	2.9	2.4	2.3	2.2	2.2
Employee expense	1.5	1.1	1.1	1.0	1.0
PPOP	4.0	3.8	4.2	4.4	4.5
Provisions	1.5	1.2	1.0	1.1	1.1
Tax expense	0.7	0.7	0.8	0.9	0.9
RoAUM (%)	1.9	2.0	2.4	2.5	2.6
Leverage ratio (x)	7.1	6.5	6.2	6.5	6.8
RoE (%)	13.3	12.7	14.5	16.3	17.5

Quarterly data					
Rs mn, Y/E Mar	Q1FY26	Q2FY26	Q3FY26	Q4FY26	Q1FY27
NII	28,662	30,040	33,148	34,775	35,710
NIM (%)	5.5	5.0	5.1	5.3	5.2
PPOP	22,913	22,767	24,527	25,597	28,349
PAT	10,415	11,155	12,638	14,653	16,256
EPS (Rs)	2.63	2.74	2.99	3.56	3.86

Source: Company, Emkay Research


This report is intended for Team White Marque Solutions (team.emkay@whitemarqueresolutions)

RECOMMENDATION HISTORY - DETAILS

Date	Closing Price (Rs)	TP (Rs)	Rating	Analyst
29-Jul-26	362	410	Add	Avinash Singh
05-Jul-26	349	390	Add	Avinash Singh
18-Jun-26	345	390	Add	Avinash Singh
24-Apr-26	337	390	Add	Avinash Singh
06-Apr-26	308	350	Add	Avinash Singh
17-Mar-26	311	380	Add	Avinash Singh
20-Jan-26	358	380	Add	Avinash Singh
06-Jan-26	362	360	Add	Avinash Singh
12-Nov-25	325	360	Add	Avinash Singh
29-Oct-25	326	360	Add	Avinash Singh
13-Oct-25	331	360	Add	Avinash Singh

Source: Company, Emkay Research

RECOMMENDATION HISTORY - TREND



Source: Company, Bloomberg, Emkay Research

This report is intended for Team White Marque Solutions (team.emkay@whitemarquesolutions)

GENERAL DISCLOSURE/DISCLAIMER BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL):

Emkay Global Financial Services Limited (CIN-L67120MH1995PLC084899) and its affiliates are a full-service, brokerage, investment banking, investment management and financing group. Emkay Global Financial Services Limited (EGFSL) along with its affiliates are participants in virtually all securities trading markets in India. EGFSL was established in 1995 and is one of India's leading brokerage and distribution house. EGFSL is a corporate trading member of BSE Limited (BSE), National Stock Exchange of India Limited (NSE), MCX Stock Exchange Limited (MCX-SX), Multi Commodity Exchange of India Ltd (MCX) and National Commodity & Derivatives Exchange Limited (NCDEX) (hereinafter referred to be as "Stock Exchange(s)"). EGFSL along with its [affiliates] offers the most comprehensive avenues for investments and is engaged in the businesses including stock broking (Institutional and retail), merchant banking, commodity broking, depository participant, portfolio management and services rendered in connection with distribution of primary market issues and financial products like mutual funds, fixed deposits. Details of associates are available on our website i.e. www.emkayglobal.com.

EGFSL is registered as Research Analyst with the Securities and Exchange Board of India ("SEBI") bearing registration Number INH000000354 as per SEBI (Research Analysts) Regulations, 2014. EGFSL hereby declares that it has not defaulted with any Stock Exchange nor its activities were suspended by any Stock Exchange with whom it is registered in last five years. However, SEBI and Stock Exchanges had conducted their routine inspection and based on their observations have issued advice letters or levied minor penalty on EGFSL for certain operational deviations in ordinary/routine course of business. EGFSL has not been debarred from doing business by any Stock Exchange / SEBI or any other authorities; nor has its certificate of registration been cancelled by SEBI at any point of time.

EGFSL offers research services to its existing clients as well as prospects. The analyst for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject company or companies and its or their securities, and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report.

This report is based on information obtained from public sources and sources believed to be reliable, but no independent verification has been made nor is its accuracy or completeness guaranteed. This report and information herein is solely for informational purpose and shall not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Though disseminated to all the clients simultaneously, not all clients may receive this report at the same time. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient.

EGFSL and/or its affiliates may seek investment banking or other business from the company or companies that are the subject of this material. EGFSL may have issued or may issue other reports (on technical or fundamental analysis basis) of the same subject company that are inconsistent with and reach different conclusion from the information, recommendations or information presented in this report or are contrary to those contained in this report. Users of this report may visit www.emkayglobal.com to view all Research Reports of EGFSL. The views and opinions expressed in this document may or may not match or may be contrary with the views, estimates, rating, and target price of the research published by any other analyst or by associate entities of EGFSL; our proprietary trading, investment businesses or other associate entities may make investment decisions that are inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest including but not limited to those stated herein. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein. All material presented in this report, unless specifically indicated otherwise, is under copyright to Emkay. None of the material, nor its content, nor any copy of it, may be altered in any way, transmitted to, copied or distributed to any other party, without the prior express written permission of EGFSL. All trademarks, service marks and logos used in this report are trademarks or registered trademarks of EGFSL or its affiliates. The information contained herein is not intended for publication or distribution or circulation in any manner whatsoever and any unauthorized reading, dissemination, distribution or copying of this communication is prohibited unless otherwise expressly authorized. Please ensure that you have read "Risk Disclosure Document for Capital Market and Derivatives Segments" as prescribed by Securities and Exchange Board of India before investing in Indian Securities Market. In so far as this report includes current or historic information, it is believed to be reliable, although its accuracy and completeness cannot be guaranteed.

This report has not been reviewed or authorized by any regulatory authority. There is no planned schedule or frequency for updating research report relating to any issuer/subject company.

Please contact the primary analyst for valuation methodologies and assumptions associated with the covered companies or price targets.

Disclaimer for U.S. persons only: Research report is a product of Emkay Global Financial Services Ltd., under Marco Polo Securities 15a6 chaperone service, which is the employer of the research analyst(s) who has prepared the research report. The research analyst(s) preparing the research report is/are resident outside the United States (U.S.) and are not associated persons of any U.S. regulated broker-dealer and therefore the analyst(s) is/are not subject to supervision by a U.S. broker-dealer, and is/are not required to satisfy the regulatory licensing requirements of Financial Institutions Regulatory Authority (FINRA) or required to otherwise comply with U.S. rules or regulations regarding, among other things, communications with a subject company, public appearances and trading securities held by a research analyst account.

This report is intended for distribution to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the U.S. Securities and Exchange Act, 1934 (the Exchange Act) and interpretations thereof by U.S. Securities and Exchange Commission (SEC) in reliance on Rule 15a 6(a)(2). If the recipient of this report is not a Major Institutional Investor as specified above, then it should not act upon this report and return the same to the sender. Further, this report may not be copied, duplicated and/or transmitted onward to any U.S. person, which is not the Major Institutional Investor. In reliance on the exemption from registration provided by Rule 15a-6 of the Exchange Act and interpretations thereof by the SEC in order to conduct certain business with Major Institutional Investors. Emkay Global Financial Services Ltd. has entered into a chaperoning agreement with a U.S. registered broker-dealer, Marco Polo Securities Inc. ("Marco Polo"). Transactions in securities discussed in this research report should be effected through Marco Polo or another U.S. registered broker dealer.

This report is intended for Team White Marque Solutions (team.emkay@whitemarquessolutions.com)

RESTRICTIONS ON DISTRIBUTION

This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation. Except otherwise restricted by laws or regulations, this report is intended only for qualified, professional, institutional or sophisticated investors as defined in the laws and regulations of such jurisdictions. Specifically, this document does not constitute an offer to or solicitation to any U.S. person for the purchase or sale of any financial instrument or as an official confirmation of any transaction to any U.S. person. Unless otherwise stated, this message should not be construed as official confirmation of any transaction. No part of this document may be distributed in Canada or used by private customers in United Kingdom.

ANALYST CERTIFICATION BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL)

The research analyst(s) primarily responsible for the content of this research report, in part or in whole, certifies that the views about the companies and their securities expressed in this report accurately reflect his/her personal views. The analyst(s) also certifies that no part of his/her compensation was, is, or will be, directly or indirectly, related to specific recommendations or views expressed in the report. The research analyst (s) primarily responsible of the content of this research report, in part or in whole, certifies that he or his associated persons¹ may have served as an officer, director or employee of the issuer or the new listing applicant (which includes in the case of a real estate investment trust, an officer of the management company of the real estate investment trust; and in the case of any other entity, an officer or its equivalent counterparty of the entity who is responsible for the management of the issuer or the new listing applicant). The research analyst(s) primarily responsible for the content of this research report or his associate may have Financial Interests² in relation to an issuer or a new listing applicant that the analyst reviews. EGFSL has procedures in place to eliminate, avoid and manage any potential conflicts of interests that may arise in connection with the production of research reports. The research analyst(s) responsible for this report operates as part of a separate and independent team to the investment banking function of the EGFSL and procedures are in place to ensure that confidential information held by either the research or investment banking function is handled appropriately. There is no direct link of EGFSL compensation to any specific investment banking function of the EGFSL.

¹ An associated person is defined as (i) who reports directly or indirectly to such a research analyst in connection with the preparation of the reports; or (ii) another person accustomed or obliged to act in accordance with the directions or instructions of the analyst.

² Financial Interest is defined as interest that are commonly known financial interest, such as investment in the securities in respect of an issuer or a new listing applicant, or financial accommodation arrangement between the issuer or the new listing applicant and the firm or analysis. This term does not include commercial lending conducted at the arm's length, or investments in any collective investment scheme other than an issuer or new listing applicant notwithstanding the fact that the scheme has investments in securities in respect of an issuer or a new listing applicant.

COMPANY-SPECIFIC / REGULATORY DISCLOSURES BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL):

Disclosures by Emkay Global Financial Services Limited (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company(s) covered in this report:-

- EGFSL, its subsidiaries and/or other affiliates and Research Analyst or his/her associate/relative's may have Financial Interest/proprietary positions in the securities recommended in this report as of September 20, 2026
- EGFSL, and/or Research Analyst does not market make in equity securities of the issuer(s) or company(ies) mentioned in this Report

Disclosure of previous investment recommendation produced:

- EGFSL may have published other investment recommendations in respect of the same securities / instruments recommended in this research report during the preceding 12 months. Please contact the primary analyst listed in the first page of this report to view previous investment recommendations published by EGFSL in the preceding 12 months.
- EGFSL, its subsidiaries and/or other affiliates and Research Analyst or his/her relative's may have material conflict of interest in the securities recommended in this report as of September 20, 2026
- EGFSL, its affiliates and Research Analyst or his/her associate/relative's may have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the September 20, 2026
- EGFSL or its associates may have managed or co-managed public offering of securities for the subject company in the past twelve months.
- EGFSL, its affiliates and Research Analyst or his/her associate may have received compensation in whatever form including compensation for investment banking or merchant banking or brokerage services or for products or services other than investment banking or merchant banking or brokerage services from securities recommended in this report (subject company) in the past 12 months.
- EGFSL, its affiliates and/or Research Analyst or his/her associate may have received any compensation or other benefits from the subject company or third party in connection with this research report.

Emkay Rating Distribution

Ratings	Expected Return within the next 12-18 months.
BUY	>15% upside
ADD	5-15% upside
REDUCE	5% upside to 15% downside
SELL	>15% downside

Emkay Global Financial Services Ltd.

CIN - L67120MH1995PLC084899

7th Floor, The Ruby, Senapati Bapat Marg, Dadar - West, Mumbai - 400028. India

Tel: +91 22 66121212 Fax: +91 22 66121299 Web: www.emkayglobal.com

This report is intended for Team White Marque Solutions (team.emkay@whitemarquessolutions)

OTHER DISCLAIMERS AND DISCLOSURES:**Other disclosures by Emkay Global Financial Services Limited (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company(s) :-**

EGFSL or its associates may have financial interest in the subject company.

Research Analyst or his/her associate/relative's may have financial interest in the subject company.

EGFSL or its associates and Research Analyst or his/her associate/ relative's may have material conflict of interest in the subject company. The research Analyst or research entity (EGFSL) have not been engaged in market making activity for the subject company.

EGFSL or its associates may have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of public appearance or publication of Research Report.

Research Analyst or his/her associate/relatives may have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of public appearance or publication of Research Report.

Research Analyst may have served as an officer, director or employee of the subject company.

EGFSL or its affiliates may have received any compensation including for investment banking or merchant banking or brokerage services from the subject company in the past 12 months. . Emkay may have issued or may issue other reports that are inconsistent with and reach different conclusion from the information, recommendations or information presented in this report or are contrary to those contained in this report. Emkay Investors may visit www.emkayglobal.com to view all Research Reports. The views and opinions expressed in this document may or may not match or may be contrary with the views, estimates, rating, and target price of the research published by any other analyst or by associate entities of Emkay; our proprietary trading, investment businesses or other associate entities may make investment decisions that are inconsistent with the recommendations expressed herein. EGFSL or its associates may have received compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past 12 months. EGFSL or its associates may have received any compensation or other benefits from the Subject Company or third party in connection with the research report. EGFSL or its associates may have received compensation from the subject company in the past twelve months. Subject Company may have been client of EGFSL or its affiliates during twelve months preceding the date of distribution of the research report and EGFSL or its affiliates may have co-managed public offering of securities for the subject company in the past twelve months.

This report is intended for Team White Marque Solutions (team.emkay@whitemarquesolutions.com)